312 related articles for article (PubMed ID: 30096106)
1. Phase 3 Study of OnabotulinumtoxinA Distributed Between Frontalis, Glabellar Complex, and Lateral Canthal Areas for Treatment of Upper Facial Lines.
De Boulle K; Werschler WP; Gold MH; Bruce S; Sattler G; Ogilvie P; Street J; Larsen KE; Yushmanova I; Lei X; Lee E; Vitarella D; Mao C
Dermatol Surg; 2018 Nov; 44(11):1437-1448. PubMed ID: 30096106
[TBL] [Abstract][Full Text] [Related]
2. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Repeated OnabotulinumtoxinA Treatments in Subjects With Crow's Feet Lines and Glabellar Lines.
Carruthers J; Rivkin A; Donofrio L; Bertucci V; Somogyi C; Lei X; Davis PG; Campo A; Beddingfield FC
Dermatol Surg; 2015 Jun; 41(6):702-11. PubMed ID: 25993609
[TBL] [Abstract][Full Text] [Related]
3. Forehead Line Treatment With OnabotulinumtoxinA in Subjects With Forehead and Glabellar Facial Rhytids: A Phase 3 Study.
Fagien S; Cohen JL; Coleman W; Monheit G; Carruthers J; Street J; Larsen KE; Yushmanova I; Lei X; Lee E; Vitarella D; Mao C
Dermatol Surg; 2017 Dec; 43 Suppl 3():S274-S284. PubMed ID: 33065953
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, Patient-Reported Outcomes, and Safety in Male Subjects Treated With OnabotulinumtoxinA for Improvement of Moderate to Severe Horizontal Forehead Lines.
Keaney TC; Cavallini M; Leys C; Rossi A; Drinkwater A; Manson Brown S; Garcia JK; Mao C
Dermatol Surg; 2020 Feb; 46(2):229-239. PubMed ID: 31343446
[TBL] [Abstract][Full Text] [Related]
5. OnabotulinumtoxinA for Simultaneous Treatment of Upper Facial Lines: Subject-Reported Satisfaction and Impact From a Phase 3 Study.
Rivkin AZ; Ogilvie P; Dayan S; Yoelin SG; Weichman BM; Garcia JK
Dermatol Surg; 2020 Jan; 46(1):50-60. PubMed ID: 30829771
[TBL] [Abstract][Full Text] [Related]
6. Safety, Efficacy, and Patient Satisfaction With OnabotulinumtoxinA for the Treatment of Upper Facial Lines in Japanese Subjects.
Kawashima M; Harii K; Horiuchi Y; Seidman E; Lei X; Hopfinger R; Lee E
Dermatol Surg; 2020 Apr; 46(4):483-490. PubMed ID: 31517663
[TBL] [Abstract][Full Text] [Related]
7. Subject satisfaction with onabotulinumtoxinA treatment of glabellar and lateral canthal lines using a new patient-reported outcome measure.
Rivers JK; Bertucci V; McGillivray W; Muhn C; Rosen N; Solish N; Weichman BM; Wheeler S; Daniels SR; Gallagher CJ
Dermatol Surg; 2015 Aug; 41(8):950-9. PubMed ID: 26218728
[TBL] [Abstract][Full Text] [Related]
8. OnabotulinumtoxinA (Botox) in the Treatment of Crow's Feet Lines in Japanese Subjects.
Harii K; Kawashima M; Furuyama N; Lei X; Hopfinger R; Lee E
Aesthetic Plast Surg; 2017 Oct; 41(5):1186-1197. PubMed ID: 28733805
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, Patient-Reported Outcomes, and Safety for Millennial Subjects Treated With OnabotulinumtoxinA for Moderate to Severe Horizontal Forehead Lines.
Palm MD; Few J; Patel T; Safa M; Drinkwater A; Mao C; Garcia JK
Dermatol Surg; 2020 May; 46(5):653-661. PubMed ID: 31625954
[TBL] [Abstract][Full Text] [Related]
10. OnabotulinumtoxinA for Treatment of Forehead and Glabellar Lines: Subject-Reported Satisfaction and Impact From a Phase 3 Double-Blind Study.
Ogilvie P; Rivkin AZ; Dayan S; Yoelin SG; Weichman BM; Garcia JK
Dermatol Surg; 2019 May; 45(5):689-699. PubMed ID: 31034447
[TBL] [Abstract][Full Text] [Related]
11. Duration of Clinical Efficacy of OnabotulinumtoxinA in Crow's Feet Lines: Results from Two Multicenter, Randomized, Controlled Trials.
Baumann L; Dayan S; Connolly S; Silverberg N; Lei X; Drinkwater A; Gallagher CJ
Dermatol Surg; 2016 May; 42(5):598-607. PubMed ID: 27110893
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of OnabotulinumtoxinA Treatment of Forehead Lines: A Multicenter, Randomized, Dose-Ranging Controlled Trial.
Solish N; Rivers JK; Humphrey S; Muhn C; Somogyi C; Lei X; Bhogal M; Caulkins C
Dermatol Surg; 2016 Mar; 42(3):410-9. PubMed ID: 26863598
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of onabotulinumtoxinA for the treatment of crows feet lines: a multicenter, randomized, controlled trial.
Carruthers A; Bruce S; de Coninck A; Connolly S; Cox SE; Davis PG; Campo A; Lei X; Somogyi C; Lee E; McLean H; Beddingfield F
Dermatol Surg; 2014 Nov; 40(11):1181-90. PubMed ID: 25347451
[TBL] [Abstract][Full Text] [Related]
14. High Patient Satisfaction for up to 6 Months With OnabotulinumtoxinA Treatment for Upper Facial Lines.
Cohen JL; Fagien S; Ogilvie P; De Boulle K; Carruthers J; Cox SE; Kelly R; Garcia JK; Sangha S
Dermatol Surg; 2022 Nov; 48(11):1191-1197. PubMed ID: 36342250
[TBL] [Abstract][Full Text] [Related]
15. Treatment of crow's feet lines and forehead lines with Botox (onabotulinumtoxinA): Development, insights, and impact.
Carruthers A; Carruthers J; De Boulle K; Lowe N; Lee E; Brin MF
Medicine (Baltimore); 2023 Jul; 102(S1):e32496. PubMed ID: 37499083
[TBL] [Abstract][Full Text] [Related]
16. OnabotulinumtoxinA for Treatment of Moderate to Severe Crow's Feet Lines: A Review.
Carruthers A; Bruce S; Cox SE; Kane MA; Lee E; Gallagher CJ
Aesthet Surg J; 2016 May; 36(5):591-7. PubMed ID: 26979457
[TBL] [Abstract][Full Text] [Related]
17. Phase I/III Clinical Trial to Evaluate the Safety and Efficacy of a New Botulinum Toxin (HU-014) Versus OnabotulinumtoxinA in Subjects With Moderate-to-Severe Crow's Feet Lines.
Han HS; Yoo KH; Lee JS; Huh CH; Kwon SH; Lee YW; Kim BJ
Dermatol Surg; 2021 Apr; 47(4):e127-e131. PubMed ID: 33795571
[TBL] [Abstract][Full Text] [Related]
18. Pooled Subject-Reported Outcomes From 2 Phase 3 Studies of OnabotulinumtoxinA for Simultaneous Treatment of Forehead and Glabellar Lines.
Ogilvie P; Rivkin AZ; Dayan S; Yoelin SG; Larsen KE; Varon S; Garcia JK
Dermatol Surg; 2020 Jul; 46(7):950-957. PubMed ID: 31567611
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of AbobotulinumtoxinA for the Treatment of Glabellar Lines in Chinese Patients: A Pivotal, Phase 3, Randomized, Double-Blind and Open-Label Phase Study.
Wu Y; Fang F; Lai W; Li C; Li L; Liu Q; Lu J; Pang X; Sun J; Shi X; Picaut P; Prygova I; Andriopoulos B; Sun Q
Aesthetic Plast Surg; 2023 Feb; 47(1):351-364. PubMed ID: 36536093
[TBL] [Abstract][Full Text] [Related]
20. OnabotulinumtoxinA treatment of moderate to severe glabellar lines in Chinese subjects after laser therapy: A prospective, open-label, noncomparative study.
Wu Y; Lu Z; Xie Y; Zhang W; Chen X; Shi Y; Li Q; Halstead M; Rogers JD; Silberberg M
J Cosmet Laser Ther; 2018 Oct; 20(5):278-286. PubMed ID: 29498553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
